Progyny (PGNY) Cash & Equivalents (2018 - 2026)

Progyny (PGNY) has 9 years of Cash & Equivalents data on file, last reported at $131.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 20.48% year-over-year to $131.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $131.6 million (up 20.48% YoY) and the FY2025 annual result came in at $112.2 million, down 30.85% from the prior year.
• Cash & Equivalents grew to $131.6 million in Q1 2026 per PGNY's latest filing, from $112.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $170.6 million in Q2 2023 and bottomed at $38.8 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $115.0 million (2024), against an average of $114.7 million.
• The widest annual swing landed in 2023, when Cash & Equivalents jumped 300.09%; it then slumped 44.33% in 2024.
• Tracing PGNY's Cash & Equivalents over 5 years: stood at $120.1 million in 2022, then decreased by 18.97% to $97.3 million in 2023, then jumped by 66.82% to $162.3 million in 2024, then tumbled by 30.85% to $112.2 million in 2025, then advanced by 17.26% to $131.6 million in 2026.
• Per Business Quant, the three latest PGNY Cash & Equivalents figures stand at $131.6 million (Q1 2026), $112.2 million (Q4 2025), and $134.0 million (Q3 2025).

Peer Comparison